ATE190351T1 - Polypeptide, von endonexin 2 stammend, mit hepatitis b virus rezeptor aktivität und deren verwendungen in diagnotischen und pharmazeutischen zusammensetzungen - Google Patents

Polypeptide, von endonexin 2 stammend, mit hepatitis b virus rezeptor aktivität und deren verwendungen in diagnotischen und pharmazeutischen zusammensetzungen

Info

Publication number
ATE190351T1
ATE190351T1 AT93915810T AT93915810T ATE190351T1 AT E190351 T1 ATE190351 T1 AT E190351T1 AT 93915810 T AT93915810 T AT 93915810T AT 93915810 T AT93915810 T AT 93915810T AT E190351 T1 ATE190351 T1 AT E190351T1
Authority
AT
Austria
Prior art keywords
endonexin
hepatitis
diagnostic
pharmaceutical compositions
receptor activity
Prior art date
Application number
AT93915810T
Other languages
English (en)
Inventor
Sing-Hiem Yap
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of ATE190351T1 publication Critical patent/ATE190351T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT93915810T 1992-07-08 1993-07-06 Polypeptide, von endonexin 2 stammend, mit hepatitis b virus rezeptor aktivität und deren verwendungen in diagnotischen und pharmazeutischen zusammensetzungen ATE190351T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92401971 1992-07-08
PCT/EP1993/001745 WO1994001554A1 (en) 1992-07-08 1993-07-06 Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ATE190351T1 true ATE190351T1 (de) 2000-03-15

Family

ID=8211682

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93915810T ATE190351T1 (de) 1992-07-08 1993-07-06 Polypeptide, von endonexin 2 stammend, mit hepatitis b virus rezeptor aktivität und deren verwendungen in diagnotischen und pharmazeutischen zusammensetzungen

Country Status (12)

Country Link
EP (2) EP0672136B1 (de)
JP (2) JPH07509776A (de)
AT (1) ATE190351T1 (de)
AU (1) AU676483B2 (de)
CA (1) CA2139735A1 (de)
DE (1) DE69328035T2 (de)
DK (1) DK0672136T3 (de)
ES (1) ES2146231T3 (de)
GR (1) GR3033482T3 (de)
PT (1) PT672136E (de)
SG (1) SG46493A1 (de)
WO (1) WO1994001554A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0741144B1 (de) * 1994-11-11 2002-07-24 Noboru Kaneko Monoklonaler antikörper gegen antiannexin-v, verfahren zu seiner herstellung und seiner verwendung
JP2001508054A (ja) * 1996-12-30 2001-06-19 イノジェネティックス・ナムローゼ・フェンノートシャップ ＨＢｓＡｇ由来アネキシンＶ結合ポリペプチドおよびその使用
ATE349225T1 (de) * 1997-11-06 2007-01-15 Innogenetics Nv Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv
US6344362B1 (en) 1998-03-12 2002-02-05 Ministero Dell Universita'e Della Ricerca Scientifica E Tecnologica (M.U.R.S.T. ) Use of a recombinant protein as receptor of a hepatitis virus
IT1299581B1 (it) * 1998-03-12 2000-03-16 Ministero Dell Uni Della Ricer Uso di una proteina ricombinante come recettore di un virus dell'epatite
CN1315963A (zh) * 1998-09-01 2001-10-03 基因创新有限公司 结合膜联蛋白的苯并二氮杂䓬类和苯并硫杂吖庚因衍生物和hbsag肽,其组合物和用途
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
DE60219611T2 (de) 2001-02-21 2007-12-27 Alavita Pharmaceuticals, Inc., Mountain View Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US20060057591A1 (en) * 2004-09-15 2006-03-16 Canadian Blood Services Method for preventing viral infection
ES2494840T3 (es) 2005-03-15 2014-09-16 Fujirebio Europe N.V. Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas
US8383879B2 (en) * 2009-12-04 2013-02-26 Academia Sinica Non-human animal disease mode for hepatitis B virus-associated disease
JP6445447B2 (ja) * 2012-11-12 2018-12-26 ルプレヒト−カールス−ウニヴェルジテート ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ Ｈｂｖ及び／又はｈｄｖ感受性の細胞、細胞株及び非ヒト動物の開発

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI861417A0 (fi) * 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
PT87083B (pt) * 1987-03-28 1992-07-31 Boehringer Ingelheim Int Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem
EP0288198A3 (de) * 1987-04-20 1989-03-29 Takeda Chemical Industries, Ltd. Peptidherstellung
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE3737239A1 (de) * 1987-11-03 1989-10-12 Behringwerke Ag Gentechnische herstellung von anticoagulatorischem protein pp4
EP0339285A3 (de) * 1988-03-31 1989-11-29 RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) Rekombinantes Endonexin II
FR2637184A1 (fr) * 1988-10-05 1990-04-06 Inst Nat Sante Rech Med Anticorps monoclonal reconnaissant une region pre-s1 de la grande proteine d'enveloppe du virus de l'hepatite b et ses applications, notamment pour le diagnostic in vitro et le traitement de l'hepatite b
EP0389983A3 (de) * 1989-03-31 1991-01-16 Abbott Laboratories Monoklonale Antikörper gegen PreS2- und PreS1-Polypeptide des Umhüllungsproteins des Hepatite B-Virus
DE4012341A1 (de) * 1990-04-18 1991-10-24 Behringwerke Ag Monoklonale antikoerper gegen pp4, verfahren zu ihrer herstellung und ihre verwendung

Also Published As

Publication number Publication date
DK0672136T3 (da) 2000-08-21
DE69328035D1 (de) 2000-04-13
JPH07509776A (ja) 1995-10-26
CA2139735A1 (en) 1994-01-20
EP0672136A1 (de) 1995-09-20
GR3033482T3 (en) 2000-09-29
WO1994001554A1 (en) 1994-01-20
ES2146231T3 (es) 2000-08-01
DE69328035T2 (de) 2000-11-02
EP0672136B1 (de) 2000-03-08
AU676483B2 (en) 1997-03-13
AU4564693A (en) 1994-01-31
EP0968648A1 (de) 2000-01-05
JP2003189759A (ja) 2003-07-08
PT672136E (pt) 2000-08-31
SG46493A1 (en) 1998-02-20

Similar Documents

Publication Publication Date Title
ATE190351T1 (de) Polypeptide, von endonexin 2 stammend, mit hepatitis b virus rezeptor aktivität und deren verwendungen in diagnotischen und pharmazeutischen zusammensetzungen
PT725824E (pt) Epitopos de celulas t humanas imunodominantes do virus da hepatite c
ATE216225T1 (de) Diagnostische verfahren und pharmazeutische zusammensetzungen auf der basis von notch- proteinen und nukleinsäuren
ATE102956T1 (de) Polypeptide und deren derivate und deren verwendung in pharmazeutischen und diagnostischen zusammensetzungen.
LV10507A (lv) Vektors sunas eritroproteins farmaceitiska kompozicija
DK0792287T3 (da) Peptidanaloger af humant basisk myelinprotein
ATE140969T1 (de) Il-3 mit zusätzlichen cysteinresten und chemische modifikationen davon
DE69230993D1 (de) Rekombinante viren vektoren zur expression in muskelzellen
ATE189684T1 (de) Rekombinante polypeptide und peptide, dafür kodierende nukleinsäuren und ihre verwendung in der tuberkulose-diagnose
ATE199377T1 (de) Protein mit cytokinaktivität, rekombinant-dns, expressionsvektor und wirtszellen zu seiner herstellung
BR9306272A (pt) Peptídeo e composiçao farmacêutica
EA200000685A1 (ru) Комплекс ifnar2/ifn
LV11816A (lv) Implantejama zalu forma
ATE67783T1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
ES2080060T3 (es) Proteinas que tienen actividad de union a interferon-gamma.
AU3902489A (en) Non-glycosylated, recombinant human IL2 in the reduced form, the process for obtaining it and its use as a medicament
ATE136933T1 (de) Rekombinante hbsag hybridpartikel, die morphologische eigenschaften von hbsag-antigen haben und eine immunogene sequenz enthalten, die neutralisierende antikörper gegen hiv induziert oder die von diesen antikörpern erkannt ist, nukleotide sequenzen, die diese partikel codieren und sie enthaltende impfstoffe
KR910700259A (ko) T-세포 인지성 펩티드 변형에 의해 면역반응에 영향을 주는 방법
FR2655855B1 (fr) Protection genetique d'animaux contre l'infection par le virus leucemogene bovin, et provirus et virus recombinant derive de ce virus.
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee